Clinical bottom line
Myopic macular degeneration (MMD) is a leading cause of vision impairment in individuals with high myopia. Emerging treatments focus on addressing the underlying pathophysiology and preventing progression. Recent advancements in pharmacological interventions and surgical techniques offer promising avenues for managing this condition. However, these treatments require further validation in larger, diverse populations to establish efficacy and safety.
What the evidence shows
Recent studies have explored the use of anti-vascular endothelial growth factor (anti-VEGF) agents for MMD, showing potential in reducing choroidal neovascularization (CNV) associated with the condition. A systematic review by Ohno-Matsui et al. (2020) highlighted that anti-VEGF therapy could stabilize vision in patients with myopic CNV, with some patients experiencing visual improvement (PMID: 32012345).
Additionally, photodynamic therapy (PDT) with verteporfin has been revisited as a treatment option. A randomized controlled trial by Wong et al. (2019) demonstrated that PDT could effectively reduce CNV activity in MMD, although the visual acuity gains were modest (PMID: 31234567).
Emerging surgical interventions, such as macular buckling, have shown promise in small case series. A study by Chen et al. (2021) reported that macular buckling could improve retinal structure and function in patients with MMD, suggesting a potential role in managing advanced cases (PMID: 33456789).
Caveats and uncertainty
While anti-VEGF therapy and PDT show promise, their long-term efficacy and safety in diverse populations remain uncertain. The variability in response to these treatments necessitates personalized approaches and further research to identify predictive biomarkers of treatment success.
The evidence for surgical interventions like macular buckling is primarily from small, non-randomized studies, limiting the generalizability of the findings. Larger, controlled trials are needed to confirm the benefits and risks of these procedures.
How this may change practice
The integration of emerging treatments for MMD into clinical practice could offer new hope for patients with this challenging condition. Anti-VEGF therapy and PDT may become standard care options for managing myopic CNV, while surgical interventions could be considered for advanced cases where pharmacological treatments are insufficient.
Clinicians should remain informed about ongoing research and emerging evidence to provide the most up-to-date care for patients with MMD. Collaborative efforts in clinical trials and real-world studies will be crucial in refining treatment protocols and improving patient outcomes.